• Wed news: Gilead HIV pipeline. Walgreens may go private. How Trump 2.0 will affect medtech. Lilly to offer Zepbound via Ro Telehealth. Pharma’s regulatory optimism. See more on our front page

Pile of Dung

Quote

anonymous

Guest
“Our operating results continued to be negatively impacted by the effects of COVID-19 and its limitations to our access to healthcare providers during the third quarter,” said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma.

So, this is what Alan published in the earnings announcement. I wonder if he really believes this...I guess Jeff convinced him that access is the issue. Access certainly isn't hurting TUKYSA...quarter-over-quarter growth, same quarter year-over-year growth.

Our Q3 '21 net revenue is the lowest it's been since Q1 '18.

Access in 2020 was horrendous, worse than 2021. And we're saying that COVID-caused access was problematic in Q3?!? Our Q2 earnings announcement was all upbeat, no mentions of access issues. But Q1 announcement stated access difficulties.

Seems like inventory gets stuffed at distributors in Q4 and Q2, and then Q1 and Q3 inventory draw down happens, and we blame it on access. Sounds dirty to me.
 












The highest levels of leadership have been incompetent since the launch, the replacements have been worse and the CEO has no clue. That is why we are, where we are at Puma. Puma’s days are numbered. Last one out before CEO will be the biggest fool. Get out now and take care of yourself and your families. So many better opportunities with competent people out there and competitive salaries.
 












The thought of Spectrum and Puma - reminds me of the two sisters in my 600lb life. Complete zero’s for potential. Those two sisters also remind me of Joe and Alan. A pair to draw to.

SPPI ($ 2/ share) + PBYI (3.50) = 5.50. The combination (merger is too professional of term - more like a hook up at bar time on the top of the dumpster) of the two twerps companies will only delay the inevitable as neither has a future.

Alan, how is your basement? Your baby kinda ugly, AA? Share price 4 years ago = $120 ish vs. today - $3.50… bravo Alan Auerback. Nobody respects or believes you Alan. Hands are tied. Street cred is nothing. Recovery potential is kinda like 4th and long from your own 1, down 10 with 30 seconds on the clock.

Might be time to punt and start your 3rd company. Here’s an idea, call it Lion , hire Bert Lahr from the wizard of oz and sell a courage pill, Alan.
 






It is obvious that AA doesn’t know how to run a business. If he weren’t the founder, he would have been replaced by now. Let him stay at the helm of this Titanic failure while the rest get in the life boats now! Don’t go down with this crappy (pun intended) ship.
 












Only Stage 2, you must have used Alan Aurback’s dose escalation protocol?

Yes, of course, that solved the DC and diarrhea problem for Nerlynx.

Alan Auerbach - “ Don’t worry, we’ve got diarrhea problem solved (sic)! “
 






Only Stage 2, you must have used Alan Aurback’s dose escalation protocol?

Yes, of course, that solved the DC and diarrhea problem for Nerlynx.

Alan Auerbach - “ Don’t worry, we’ve got diarrhea problem solved (sic)! “
 






This drug should have never been approved. It causes more harm than the dismal benefit of 2% and the DC rate of 80% by the first refill. Patients are soiling their pants throughout the day and night. The trial was amended mid-stage and he cherry picked the data. Alan’s greed caught up to him because he could have sold it at approval for $180/share.
 


















anonymous said:
We will make headlines at SABCS, buyout at $44 i’m hearing.
Click to expand...
Really, grasshopper? Are you sure you’re not hearing the gushing of the wind between your ears!
$44?? Alan, is that you? No way, of course not. Alan would look at $44 as unacceptable for an “asset” like Nerlynx.
Alan has so little credibility on Wall Street that they will never let this little turd squirter drug company get near $44!
 












PBYI $250 in 2016 Now in the $3’s. Puma will make the Harvard Business Review as the scam of the century along with Enron and Madoff. This is a shell company in disguise.
 












anonymous said:
PBYI $250 in 2016 Now in the $3’s. Puma will make the Harvard Business Review as the scam of the century along with Enron and Madoff. This is a shell company in disguise.
Click to expand...
Great point, even high in launch era with Nerlynx was $100 plus range with talk of a BO.
- 97% of the air taken from the PBYI bubble since. What CEO survives while equity evaporates at that pace? If not Madoff redo, it could be a good trivia question some day.
Of course, it’s the sales teams fault, right Alan? So sad that you are the biggest loser vs the chump change lost with our piddly RSU’s.
 






Most boards would of fired the CEO already but not the Puma board. Look it up he was worth $1.2 Billion in 2015 now maybe a measly $10Million. Over 99% of his wealth gone due to greed when he could of sold it for $200 per share. But wait, blame it on the previous VP’s and fire all of them. WELL He has it all solved now with his new Amgen puppets. Jeff the along with his 3 Amgen Ho,Ho, Hoe’s will make history.
 












anonymous said:
Can’t wait for Alan and Puma to be featured on American Greed in 6 months. The shit is hitting the fan.
Click to expand...

AA should be led out of his basement in handcuffs. How many millions in fines for lying to investors did he cost Puma? In addition to share price depreciation because of his lack of competency and integrity? Medical community knows him for what he is - a zero!

AA should be personably responsible for those penalties. Shame on spineless board for not forcing his resignation. Puma will soon be irrelevant. Oops, it already is!
 






Top Bottom
Back
Quote